On April 22, 2026, Acting Attorney General Todd Blanche signed an order placing state-licensed medical marijuana into Schedule III of the Controlled Substances Act. The cannabis industry declared it a turning point. In certain respects, it is.

But turning points are not endpoints. And for California cannabis retailers who operate in the most complex, most taxed, and most litigated cannabis market in the country, the April 22 order resolves far less than the headlines suggest.

The §280E Problem, Revisited

Section 280E was enacted in 1982 in response to a tax court decision that allowed a convicted drug trafficker to deduct ordinary business expenses. Congress’s response was blunt: no deduction or credit shall be allowed for any amount paid or incurred in carrying on a trade or business that consists of trafficking in controlled substances prohibited by federal or state law. Only the cost of goods sold (or “cogs”, which is treated as an adjustment to gross income rather than a deduction) survives.

The practical consequence is financial absurdity. Cannabis businesses are taxed not on net income but on a fictional gross margin that bears little relationship to actual profitability. Effective tax rates routinely exceed 70% of gross revenue and, in loss years, can exceed 100% of cash flow. The tax obligation exists regardless of whether the business is solvent. The statute thus becomes a primary driver of insolvency, causing businesses to appear profitable for tax purposes at the precise moment they are failing.

For much of the cannabinoid supply market, the model has been simple: make the molecule, test the batch, sell the material.

If the product meets basic specifications, passes third-party testing, and can be produced at a competitive price, it is considered ready for market. That model has supported much of the consumer cannabinoid industry, where buyers often evaluate supply through potency, purity, availability, pricing, and a certificate of analysis.

Healthcare requires a different standard.

As cannabinoids begin moving into more serious functional, medical, and healthcare-oriented channels, the question becomes larger than whether a cannabinoid can be produced and sold. The question becomes whether that cannabinoid can support a defined clinical or functional application.

That is the shift now beginning to matter: from supplying cannabinoid material to developing cannabinoid ingredients.

Over the last several years, we have spent a lot of time studying how cannabis retailers make purchasing decisions.

Not just which products they buy, or how much they buy, but the entire sequence of events that begins once a buyer decides inventory needs to be ordered.

That sequence matters more than most operators realize.

In cannabis retail, inventory problems usually get diagnosed after the fact. A store has too much aging product. Cash is tied up in categories that are not moving. A vendor invoice arrives that does not match expectations. A buyer realizes a product was reordered twice. A store team receives items that were never supposed to be accepted.

By the time these issues become visible, the inventory is already in the building.

For years, cannabis operators have accepted labeling inefficiencies as an unavoidable cost of doing business. Yet, many facilities still rely on fragmented, manual workflows that require employees to export spreadsheets, copy cannabinoid results, and rekey intricate terpene data into static label templates. This traditional approach actively drains productivity, inflates labor costs, and introduces unnecessary opportunities for human error. Fortunately, a new generation of labeling technology is changing that reality.

To solve this dilemma, the cannabis industry has long desired a more integrated, streamlined approach. By connecting directly to Metrc, a modernized labeling platform effectively eliminates the manual data entry that has traditionally stalled supply chains. Instead of rebuilding templates for every batch, users can now access real-time package information straight from the source of truth to auto-populate compliant labels. This is precisely where genuine workflow innovation delivers measurable bottom-line value.

Designed specifically to erase this administrative burden, the QRlogix Software’s Metrc integration offers ready-to-print, state-specific label templates that are fully mapped to Metrc data fields. Because 100% of the Metrc data is automatically available within the system, the need for manual data entry is eliminated. Rather than typing out cannabinoid values, terpene profiles, or harvest information, users simply select the specific Metrc package they intend to print. The software handles the rest, transforming a once-tedious facility bottleneck into a remarkably simple workflow: Click. Click. Print!

This automation proves especially critical for multi-state operators navigating the fractured landscape of regional compliance. Different jurisdictions mandate wildly different warnings, layouts, and tracking metrics. Preconfigured, state-specific templates solve this challenge by providing compliant, ready-to-use designs out of the box. Because these templates map directly to Metrc data, operators can launch printing operations immediately without extensive IT development, ensuring total consistency across multiple facilities.

Ultimately, the most profound impact of this digital transformation is labor efficiency that scales alongside growth. When a facility eliminates spreadsheet exports and repetitive verification loops, tasks that previously required tens of minutes are reduced to mere seconds. As commercial cannabis operations face intensifying pricing pressures and margin compression, maximizing workflow efficiency is no longer optional. By automating data population directly from Metrc, operators can decisively eliminate human error, secure compliance, and reclaim hundreds of valuable labor hours. In an industry where efficiency dictates survival, cannabis labeling can finally be as simple as it should be when partnered with QRlogix – Click. Click. Print!

Every conversation about cannabis risk follows the same script: Regulatory uncertainty, 280E, capital access, and maybe interstate commerce, depending on the room. None of that is wrong, and operators dealing with those pressures daily don’t need me to tell them they’re real.

But after more than a decade working inside this industry, watching companies scale, stumble, and sometimes collapse, I’ve come to believe the industry is looking in the wrong direction. The risks getting the most airtime are not the ones most likely to take a healthy cannabis company down. The risk that actually keeps me up at night is quieter, and it’s been there the whole time.

It lives on the floor of your dispensary, in your cultivation facility at shift change, and at the moment a new hire decides to skip a step because no one told them why it mattered. The cannabis industry has built compliance programs. It has not built compliance cultures. And that gap is about to get a lot more expensive.

The Policy Problem

Over the past several years, cannabis operators have invested heavily in what looks like compliance: SOPs, legal counsel, documentation frameworks, and licensing strategy. Those investments made sense. In the early days, getting and keeping a license was the whole game.

The Hemp Beverage Expo (HBE) heads into its second show this June in Austin, Texas, and the energy is full speed ahead — even with November 12th looming over the industry.

With policy updates shifting rapidly and operators scrambling to brainstorm contingency plans, getting in the room with businesses and advocates from across the beverage sector has never felt more urgent. The November 12th deadline is a genuine threat to the industry’s survival, and the show is positioning itself as the place where the people fighting for this category can share knowledge, compare notes, and figure out their next moves together.

Leaders from the Hemp Beverage Alliance, Coalition for Adult Beverage Alternatives, Beverage Wholesalers for Responsible Regulation, and Wine and Spirits Wholesalers of America will all take the stage in Austin to discuss their latest efforts to shape policy and educate lawmakers.

The Data Is Building

Now that hemp beverages have been on the market for a few years and revenue is growing year over year, major enterprise market research firms are starting to dedicate real resources to tracking the sector. According to NielsenIQ’s April 2026 report “Buzz Worthy: The High Rise of THC Beverages,” THC drinks generated $239 million in sales over the past 52 weeks — a striking 135% year-over-year increase.

LeafLink’s Wholesale Cannabis Pricing Guide, drawing on over 400,000 SKUs and billions of dollars in transaction data across 18 U.S. markets throughout 2025, paints a picture of the wholesale cannabis pricing continuing its downward march as markets mature and supply expands — with each market and product category telling a slightly different story.

The Big Picture

Wholesale markets continued to mature in 2025, with many categories experiencing ongoing price compression as supply increased and operators prioritized value. Edibles and ingestibles were a notable exception, with pricing remaining effectively flat year-over-year.

Category by Category

Cartridges experienced the steepest decline, with average prices falling approximately 12% year-over-year, landing at a national average of $13.86 per gram. Pre-Rolls followed closely, dropping more than 10% to $4.66 per gram, while Concentrates fell 7.5% to $9.25 per gram, and Flower posted moderate decreases.

The April 2026 Department of Justice rescheduling order landed with the weight of a decade of advocacy behind it. For an industry that has watched every other legal sector deduct its rent, payroll, and marketing costs while cannabis operators paid taxes on money they never made, the optimism is more than justified. It is earned. The uncertainty, however, is just as real.

A Quick Reminder of Current Law

Section 280E of the Internal Revenue Code prohibits businesses trafficking in Schedule I or II controlled substances from deducting ordinary business expenses. Operators may deduct the cost of goods sold under §471 and nothing else. The result is effective federal tax rates of 60 to 80 percent, and in some cases well beyond, on businesses that are licensed, regulated, and paying state taxes like any other industry. Among the largest publicly traded multi-state operators, contested 280E tax liability now exceeds $1.7 billion collectively.

Why Rescheduling Moves the Needle

The statutory logic is clean. As cannabis tax attorneys have broadly noted, a completed Schedule III reclassification could eliminate 280E by its own terms, potentially improving operator profitability overnight, in some cases dramatically.

What the April Order Actually Does

Here is where the headline optimism requires a reality check. The April 23 order covers two categories: FDA-approved cannabis products and cannabis produced by operators holding a state-issued medical license. That is it (at least for now).

Pre-rolls generated $4 billion in sales in 2025 and are projected to grow faster than any other top cannabis category, at a 10% compound annual growth rate, according to BDSA retail tracking data. Infused formats now account for 43% of the segment, and the category has grown by 271% since 2020.

That kind of volume puts a lot of pressure on operators to get the details right. And one detail that gets underestimated more than almost any other is the tube.

The tube you choose for your pre-rolls isn’t just a container. It’s a compliance asset, a brand signal, and a margin lever all at once. In a category this competitive, getting it wrong costs you more than you might expect.

The compliance picture has gotten more complicated

Child-resistant packaging has always been a baseline requirement for cannabis pre-rolls, but the specific standards those containers need to meet have shifted significantly in 2026.

SOCi’s 2026 Local Visibility Index analyzed more than 350,000 business locations across 2,751 brands and found a gap every dispensary operator should take seriously. ChatGPT recommends 1.2% of those locations. Perplexity recommends 7.4%. Gemini reaches 11%.

Google’s local 3-pack surfaces 35.9% of the same locations. That is not a small gap. It is a different search reality, and it runs on different inputs than the local SEO game cannabis operators have spent years learning.

SOCi’s CMO described the shift clearly: AI is “reducing choice,” not replacing search. Instead of giving users a page of results, AI gives them a short list. Brands that do not clear the confidence threshold do not rank lower. They disappear from the answer entirely.

For a category that cannot run paid advertising at scale, that is a serious problem. The SOCi study covered retail, food, healthcare, and other industries broadly. Cannabis was not benchmarked separately in the public report, but the structural dynamics apply with particular force to dispensaries.

The Infrastructure Gap 

The local SEO playbook cannabis operators built over the last decade was the right playbook for the environment it was built in. Strong Google Business Profile. Consistent Leafly and Weedmaps presence. Solid review volume. NAP consistency across the platforms that mattered.

Choosing between glass and plastic packaging for cannabis concentrates is a strategic decision with downstream consequences for product integrity, compliance, consumer perception, margins, and brand positioning. This article compares the two materials across five dimensions and offers a decision framework for operators to match packaging to product type, brand strategy, and operational scale.

Why packaging choice is a strategic decision

Cannabis concentrates are one of the fastest-growing categories in the legal market. The U.S. cannabis industry is projected to grow at a 12.2% compound annual rate through 2030, with concentrates capturing an increasing share as consumer preferences shift toward potency, terpene-rich profiles, and premium product experiences. Packaging has not always kept pace with the nuances of what concentrates actually need.

The choice between glass and plastic isn’t just a procurement decision. It affects how well the product holds up on the shelf, whether the brand meets compliance requirements that vary state by state, how consumers perceive the product at the point of sale, what it costs to ship and handle, and how the brand stands on sustainability. There’s no universally right answer. The right material depends on the product type, the brand position, the regulatory environment, and the scale of the operation.

What follows is a comparison across five dimensions, along with a decision framework operators can use to match packaging to strategy.

Preservation and product integrity

The first job of concentrate packaging is protecting the product from degradation. Cannabinoids and terpenes are sensitive to light, oxygen, heat, and time, and the packaging that surrounds them is often the difference between a product that delivers on its label and one that doesn’t.

Cannabis cultivation is, at its core, a controlled environment business, and air quality remains one of the most consistently underestimated variables in the operation. Contaminated batches, worker health complaints, and odor violations affecting neighboring communities can all be traced back to air-handling decisions made early in facility design or overlooked during scale-up. Mandatory testing gets attention, but prevention rarely does. The following five mistakes are showing up more and more across licensed facilities today, and each one carries the potential for high costs, both in revenue and to the brand.

Calling MERV 8 Filters Good Enough

Traditional MERV 8, the same ones that you might install in your home HVAC system, captures larger dust particles but allows bacteria, mold spores, and fine particulates to pass through freely. MERV 13, by comparison, which is qualified for hospitals, data centers, and schools, captures particles down to 0.3 microns, including the bacterial range that MERV 8 consistently misses.

During the COVID-19 pandemic, the CDC and ASHRAE aligned on MERV 13 as the baseline standard for critical air-quality environments, a threshold that cannabis cultivation facilities clearly meet given their biological sensitivity. Most modern HVAC systems are engineered to handle MERV 13 without significant airflow or performance penalties. The upgrade cost is modest, but a single failed batch from microbial contamination is not.

Most cannabis operators have a banking problem. For many, that means limited access to financial services, forcing the business to operate largely in cash and be unable to use the standard banking rails every other industry takes for granted. The banking conversation in this industry almost always stops at access. Can the business get an account? Can it keep one? 

Those are real questions, and the answer to both is yes, but they are the wrong ones to stop at. The conversation should continue into how the business is actually functioning within whatever banking access it has, and whether that access is doing the work the business needs. Having some banking is not the same as having a dependable financial infrastructure, and the gap between them does not stay confined to the finance department. It bleeds into operations, labor, vendor relationships, and growth capacity in ways most operators have never stopped to calculate. 

Every margin leak described in the following sections traces back to a banking infrastructure failure, even though none of them are ever labeled that way in a report. Courier costs, absorbed labor hours, vendor friction, untracked losses- these get filed under operations, staffing, or shrinkage. The banking infrastructure that produced them is never identified as the source, and the margin problem remains invisible because no one is looking for it in the right place.

The Costs You Can See

The visible margin hits are straightforward. Cash-heavy operations mean armored transport, on-site storage, and security overhead that eats into the bottom line before the day starts. Because cannabis businesses are largely locked out of standard card processing networks, payment acceptance gets pieced together across alternative solutions that were never designed to work together, creating fragmentation that requires manual reconciliation to function at all. Finance teams spend hours every week manually assembling a cash picture that a business with reliable banking would simply have.

Legalization has been framed as a turning point for cannabis safety, transparency, and adoption for years, but now, over a decade since recreational cannabis sales began, American consumers are taking a closer look and asking tougher questions about whether the industry is living up to that standard. 

What’s becoming clear is this: consumers are ready for a different kind of cannabis industry, one that prioritizes transparency, consistency, and clean products over just high THC percentages. 

A Clear Shift in Consumer Expectations

New consumer data from Royal Queen Seeds, conducted with The Harris Poll, points to a meaningful shift in expectations and needs. Nearly three in four cannabis consumers (72%) say they are concerned about pesticides in their cannabis. That’s a significant jump from previous years, and it reflects a broader shift in how people think about engaging with the plant.

Consumers are becoming more aware of how cannabis is produced and have a rising expectation that the industry should meet the same safety standards they demand from other products. 

Across industries, consumers are asking more questions about sourcing, ingredients, and production practices. They are more informed, more curious, and less willing to take product claims at face value. While this shift for transparency is not unique to cannabis, it should be a wake-up call for brands and operators who have created a THC potency-first business model, and that the industry, despite its regulatory structure, is not exempt from scrutiny about cleanliness.

As U.S. cannabis rescheduling moves forward and export opportunities to the European Union become available, a new certification tool to help producers prove their products meet EU standards and fight back against supply chain fraud is now available.

CSQ (Cannabis Safety & Quality), the first ANAB-accredited cannabis and hemp safety and quality certification program, announced this week the publication of its new EU GMP Addendum, kicking off a public comment period that runs through June 1, 2026. The addendum is designed to help cannabinoid producers worldwide demonstrate compliance with EudraLex Volume 4, Parts 1 & 2, and Annex 7 — the EU’s Good Manufacturing Practice (GMP) regulatory framework for medicinal herbal products.

What the Addendum Does — and Doesn’t Do

The EU GMP Addendum is not a standalone regulatory certification. Rather, it functions as a third-party validation layered on top of a producer’s existing certification issued by a recognized Competent Authority. It gives producers a documented paper trail of compliance that can be presented to potential EU buyers — a critical validation as more North American operators eye the European medical cannabis market.

The tool is also specifically aimed at curbing what CSQ calls “greenwashing” in the cannabis supply chain, a practice where imported products are falsely relabeled as EU GMP-certified before being sold across Europe.

“When a pharmacist in Europe sells a medical cannabinoid product to a patient, they shouldn’t have to question whether or not that product is safe, or if GMPs were followed, they should know without a doubt,” said Darwin Millard, CSQ’s Technical Director.

The U.S. cannabis industry generated more than $30 billion in regulated sales in 2025, yet profitability has become harder to predict. According to a recent national index report by Cannabis Benchmarks, wholesale pricing remains volatile, recently fluctuating between approximately $987 and $1,007 per pound.

In an environment where pricing moves faster than cost structures adapt, profitability is no longer driven by yield alone. It is driven by cost visibility.

Yet many operators still cannot confidently answer a simple question:

What does it truly cost to produce this batch?

Cannabis Is a Batch Manufacturing Business

Every cannabis product, from flower to edibles to pre-rolls, is produced in batches.

As cannabis becomes a globally traded medical commodity, cGMP compliance is reshaping how it is grown, handled, and transported. For operators working with imported biomass, controlling contamination and ensuring consistency across supply chains has become a defining challenge. That challenge was a central focus at the International Cannabis Business Conference in Berlin, where a panel on Good Manufacturing Practices (GMP) examined how operators can meet the European Union’s stringent standards for medical cannabis.

Moderated by Constant Ma, CEO & President of Cannactions Consulting Ltd., the session brought together cultivators, scientists, and technology providers to discuss contamination risk from cultivation through post-harvest processing and packaging.

Unlike many agricultural commodities, cannabis presents a distinct compliance challenge. It is a biological product, inherently variable from batch to batch, and highly susceptible to microbial contamination. In medical markets, particularly in Europe, variability must be tightly controlled.

“All of this is super important because with GMP, we have to make sure that our products are consistent at all times,” Ma said. “And we also have to make sure that it’s safe for the patients that are using it.”

Where Contamination Risk Begins

Panelists emphasized that contamination risk does not begin in processing. It starts in cultivation and carries through every stage of production.

Picture the moment a cannabis company’s compliance team gets copied on an email from a banking partner’s risk officer. The subject line says “Questions re: public materials.” Attached is a spreadsheet. On one side, language from the company’s Florida medical dispensary website. On the other, language from the California recreational site, the New Jersey acquisition press release, and a quote from the CEO’s interview in a trade publication eight months ago. The risk officer wants to understand how all of it reflects the same company, because from where she’s sitting, it doesn’t. 

This is not a hypothetical. It is a conversation that is becoming more frequent as financial institutions become more sophisticated in how they evaluate cannabis operators.

Inconsistent messaging across states is not a brand problem. It is an operational risk that has been misclassified, and companies that treat it as a marketing issue tend to find out the hard way that they have compliance exposure.

What Regulators and Banks Are Actually Looking At

A state regulator reviewing a multi-state operator and a financial institution conducting due diligence are doing the same thing, even if they don’t describe it that way. Both are trying to determine whether the organization they’re looking at is actually in control of itself, its operations, its decisions, and its story.

Take a company positioning itself as a premium medical operator in Florida, a value-driven recreational brand in California, and a community dispensary in New Jersey. From the inside, that probably reads as market awareness. From a regulator’s desk or a bank’s credit committee, it reads as an organization that hasn’t decided what it actually is. Localization is a legitimate strategy. Contradiction isn’t.

Cannabis packaging decisions have downstream consequences for compliance, operations, customer perception, and margins. This article offers a practical framework for evaluating packaging suppliers across five dimensions: compliance, product quality, operational fit, customization, and partnership reliability. It closes with a pre-commitment checklist that operators can use before signing any supplier agreement.

Cannabis packaging is no longer a purchasing decision. It’s a strategic one. The wrong supplier can compromise compliance, disrupt operations, damage brand perception, and erode margins in ways that far exceed any line-item savings on the invoice. And once a brand is locked in, switching suppliers mid-stride tends to be both expensive and operationally painful.

The cannabis packaging market is also crowded and uneven. Quality varies widely, regulatory requirements are shifting state by state, and the pace of change has accelerated. The Texas Department of State Health Services (DSHS) rolled out sweeping new packaging rules for consumable hemp products on March 31, 2026, giving businesses roughly 20 days of notice before the requirements took effect. For operators, that kind of timeline is a reminder that supplier selection isn’t just about today’s products. It’s about whether a supplier can keep up with what’s coming.

The framework below covers five evaluation criteria and a pre-commitment checklist. Together, they’re designed to help operators separate suppliers who can sustain a long-term relationship from those who will create friction at every turn.

Start with compliance, not price

Compliance has to be the first filter, not an afterthought. A supplier who can’t speak fluently to state-specific rules or can’t point to how their products meet current requirements is a supplier who will cost more than they save.

Driven by innovation and convenience, pre-roll sales in 2025 not only had the strongest growth of any major category, topping $3.6 billion in sales and moving 383 million units, but supplanted flower as the most units sold for the first time in the industry’s history, according to a new report from Custom Cones USA.

It’s the fifth consecutive year that pre-rolls have outperformed the industry as a whole, growing revenues 9.8% year-over-year, well ahead of the 1.5% growth rate of the entire sector. On top of that, unit sales grew 18.6%, helping lead the category to a 15.9% market share.

In total, pre-rolls have seen by far the largest growth of any category over the past five years, driving growth for the entire industry, despite having the lowest average price point of any major category at just $9.18.

“Pre-rolls are no longer an afterthought,” said Harrison Bard, CEO of Custom Cones USA. “What started as a trim byproduct, pre-rolls have matured into a highly competitive, innovation-driven category where brands are winning through quality, scale, and smart branding.”

Drawing on point-of-sale data from 15 states collected by cannabis analytics firm Headset, as well as a survey of pre-roll manufacturers from around the country, the State of the Pre-Roll Market 2026 report shines a spotlight on this growing and important category, revealing what pre-rolls are selling, how they are being sold, and who is buying them.